SCHEMBL17522136

SCHEMBL17522136

CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)COP(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGPL1 O95470 4/20 0.58
S1PR1 P21453 5/20 0.57
S1PR3 Q99500 5/20 0.57
S1PR2 O95136 4/20 0.57
S1PR4 O95977 3/20 0.57
S1PR5 Q9H228 3/20 0.57
ALDH1A1 P00352 1/20 0.57
TSPO P30536 1/20 0.57
TMEM97 Q5BJF2 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
PLA2G4A P47712 2/20 0.54
LPAR5 Q9H1C0 2/20 0.50
PTPN1 P18031 1/20 0.48
CYP2D6 P10635 2/20 0.47
SPHK1 Q9NYA1 1/20 0.47
GMNN O75496 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
THPO P40225 1/20 0.47
MTOR P42345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29472620 1.00 SGPL1 (0.58) SGPL1S1PR1S1PR3S1PR2S1PR4
SCHEMBL20510812 1.00 SGPL1 (0.58) SGPL1S1PR1S1PR3S1PR2S1PR4
SCHEMBL195872 0.91 SGPL1 (0.61) SGPL1S1PR1S1PR3S1PR2S1PR4
SCHEMBL18286333 0.91 SGPL1 (0.61) SGPL1S1PR1S1PR3S1PR2S1PR4
SCHEMBL43371 0.91 SGPL1 (0.61) SGPL1S1PR1S1PR3S1PR2S1PR4
SCHEMBL13030814 0.82 SGPL1 (0.66) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL8934971 0.82 SGPL1 (0.66) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL1273298 0.80 SGPL1 (0.63) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL861987 0.80 SGPL1 (0.63) SGPL1PLA2G4ALPAR5PTPN1LPAR6
SCHEMBL28255336 0.80 CYP2D6 (0.56) SGPL1PTPN1CYP2D6SPHK1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113347978-B Use of P1P derivatives as sepsis therapeutic agents 埃克斯索生物制药有限公司 2024-06-07 CN claimed
US-20220079960-A1 USE OF P1P DERIVATIVES AS THERAPEUTIC AGENT FOR SEPSIS AXCESO BIOPHARMACO.,LTD. (KR) 2022-03-17 US claimed
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS INC (US) 2025-10-16 US disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 EP disclosed
EP-4499052-A2 SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION Icahn School of Medicine at Mount Sinai (US) 2025-02-05 EP disclosed
EP-4465976-A1 USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION Brightseed, Inc. (US) 2024-11-27 EP disclosed
CN-113347978-B Use of P1P derivatives as sepsis therapeutic agents 埃克斯索生物制药有限公司 2024-06-07 CN disclosed
JP-2024015132-A COMPOSITION COMPRISING O-CYCLIC PHYTOSPHINGOSINE-1-PHOSPHATE FOR PREVENTING OR TREATING PARKINSON'S DISEASE エクセソ バイオファーマ カンパニー リミテッド 2024-02-01 JP disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
WO-2023210882-A1 COMPOSITION FOR BOOSTING IMMUNITY AND PREVENTING, AMELIORATING, OR TREATING PARKINSON'S DISEASE, COMPRISING O-CYCLIC PHYTOSPHINGOSINE-1-PHOSPHATE DERIVATIVE AS ACTIVE INGREDIENT 경상국립대학교산학협력단 2023-11-02 WO disclosed
EP-3995570-A1 COMPOSITION FOR PROMOTING PROLIFERATION OF STEM CELLS, CONTAINING, AS ACTIVE INGREDIENT, CP1P OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Industry-University Cooperation Foundation Hanyang University (KR) 2022-05-11 EP disclosed
WO-2022081567-A1 METHODS FOR REVERSING HEPATIC STEATOSIS BRIGHTSEED, INC. (US) 2022-04-21 WO disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
US-20220079960-A1 USE OF P1P DERIVATIVES AS THERAPEUTIC AGENT FOR SEPSIS AXCESO BIOPHARMACO.,LTD. (KR) 2022-03-17 US disclosed
CN-114127264-A Composition for promoting stem cell proliferation comprising cyclic phytosphingosine-1-phosphate or pharmaceutically acceptable salt thereof as active ingredient 汉阳大学校产学协力团 2022-03-01 CN disclosed
US-9783562-B2 Phytosphingosine-1-phosphate derivative, preparation method therefor, and composition for preventing and treating hair loss or for growing hair comprising same PHYTOS CO., LTD (KR) 2017-10-10 US disclosed
US-9783562-B2 Phytosphingosine-1-phosphate derivative, preparation method therefor, and composition for preventing and treating hair loss or for growing hair comprising same PHYTOS CO., LTD (KR) 2017-10-10 US disclosed
US-20160046656-A1 NOVEL PHYTOSPHINGOSINE-1-PHOSPHATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING HAIR LOSS OR FOR GROWING HAIR COMPRISING SAME PHYTOS CO., LTD. (KR) 2016-02-18 US disclosed
US-20160046656-A1 NOVEL PHYTOSPHINGOSINE-1-PHOSPHATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING HAIR LOSS OR FOR GROWING HAIR COMPRISING SAME PHYTOS CO., LTD. (KR) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 SGPL1 146/4885S1PR1 473/4885S1PR3 610/4885
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS APOB, APOL1, LDLR SGPL1 191/4885S1PR1 685/4885S1PR3 782/4885
US-20220079960-A1 USE OF P1P DERIVATIVES AS THERAPEUTIC AGENT FOR SEPSIS SIRT1, SELP, VASP SGPL1 259/4885S1PR1 78/4885S1PR3 181/4885
US-20160046656-A1 NOVEL PHYTOSPHINGOSINE-1-PHOSPHATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING HAIR LOSS OR FOR GROWING HAIR COMPRISING SAME SGPL1, DCTPP1, PSAP SGPL1 1/4885S1PR1 16/4885S1PR3 65/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 SGPL1 56/4885S1PR1 9/4885S1PR3 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.